Tassos Gianakakos joined MyoKardia in October 2013, bringing more than 17 years of senior leadership experience and business development and finance expertise in the biopharmaceutical industry to the company. He joined MyoKardia from MAP Pharmaceuticals (acquired by Allergan in March 2013), where he was most recently senior vice president and chief business officer. In this position, Mr. Gianakakos played an integral role in advancing the company’s two Phase 3 clinical programs and regulatory filings for LEVADEX®, and led the successful co-promotion partnership agreement for the program with Allergan, as well as a global partnership with AstraZeneca for the company’s Unit Dose Budesonide program. Prior to MAP, Mr. Gianakakos led the formation of Codexis, Inc., a spin-off of Maxygen, Inc., in 2001. At Codexis, Mr. Gianakakos served as president and senior vice president, business development, and global head of Codexis' Pharmaceuticals Business Unit. Before forming Codexis, Mr. Gianakakos was director of business development at Maxygen, where he led the company’s business development efforts for its vaccine and bio-industrial platforms, as well as financing activities including the company’s initial public offering. Prior to Maxygen, Mr. Gianakakos was a process engineer in Merck & Co.’s vaccine division.
Mr. Gianakakos holds B.Sc. degrees in chemical engineering and economics from the Massachusetts Institute of Technology, an M.Sc. in biotechnology from Northwestern University and an M.B.A. from Harvard Business School.

William C. Fairey joined MyoKardia in January 2019, as Chief Commercial Officer and Executive Vice President with nearly three decades of biopharmaceutical industry experience building and leading patient-focused and science-driven organizations. Most recently, he served as the Chief Operating Officer and Executive Vice President of ChemoCentryx, Inc., where he led the company’s commercial strategy, including the development and execution of commercialization plans for avacopan and CCX140.  Prior to ChemoCentryx, Mr. Fairey held global leadership positions with Actelion Pharmaceuticals over a period of seventeen years, most recently serving as President of Actelion Pharmaceuticals U.S. Inc., overseeing more than 400 employees and $1.5 billion in net sales in 2017 before its acquisition by Johnson & Johnson for $30 billion. At Actelion US, he helped the company gain FDA approvals and launch OPSUMIT and UPTRAVI for pulmonary arterial hypertension and VALCHLOR for cutaneous T-cell lymphoma.  Mr. Fairey also served as President of Actelion Canada and as Regional Vice President of Australia Asia Pacific, where he had oversight across the region, including founding Actelion’s first affiliates in China, Taiwan and Singapore.  Before taking on the Canadian role, Mr. Fairey was Vice President of Sales and Managed Markets in the US, where he built Actelion’s first sales and managed markets teams and established the strategies and systems to support the launch of Actelion’s first product, TRACLEER.  Before joining Actelion, Mr. Fairey held a number of commercial roles during his 12 years with Parke-Davis Pharmaceuticals US.  
Mr. Fairey holds a bachelor’s degree in Biology from the University of Oregon and earned a Master of Business Administration degree from Saint Mary’s College of California. 

Robert McDowell has over three decades of experience discovering small molecule drugs in cardiovascular disease, inflammation and oncology, with seven compounds advancing into clinical trials. Dr. McDowell has been an integral part of MyoKardia since its inception in 2012, having served as Senior Vice President of Drug Discovery through October 2017, when he was promoted to his current position. Prior to joining MyoKardia, Dr. McDowell led drug discovery at 3-V Biosciences, advancing the company's lead program into development. He previously served as vice president of research at Sunesis Pharmaceuticals, where he oversaw drug discovery, translational research and manufacturing functions. Dr. McDowell led the structural chemistry group at Axys Pharmaceuticals. Before joining Axys, Dr. McDowell was a senior scientist at Genentech, where he developed successful strategies for peptidomimetic design. Dr. McDowell has authored more than 40 peer-reviewed manuscripts and is an inventor on more than 20 issued U.S. patents.
Dr. McDowell holds a B.S. in chemistry and physics from Butler University and a Ph.D. in chemistry from the University of California at Berkeley.

Jake Bauer brings more than 15 years of biopharma industry experience.  He is currently responsible for corporate and business development, program management, portfolio strategy, alliance management, and corporate strategy functions.  From July 2014 to April 2018, he also led the finance, accounting, information technology, facilities, corporate communications, and investor relations functions as senior vice president, finance and corporate development.  
He joined MyoKardia from Ablexis, LLC, where he was vice president, business operations and head of corporate development. At Ablexis, he led the development and implementation of the company’s corporate strategy and business development activities and oversaw business operations. Prior to Ablexis Mr. Bauer was a principal at Third Rock Ventures, wherehe was actively involved in a variety of leading biopharmaceutical companies including Agios, CytomX, Global Blood Therapeutics and Zafgen. Prior to Third Rock Ventures, Mr. Bauer served in roles in the investment group at Royalty Pharma, the business development group at Endo Pharmaceuticals, and was previously a management consultant at Putnam Associates.
Mr. Bauer holds a B.Sc. in biology and a B.A. in economics from Duke University and an M.B.A. from Harvard Business School. He currently serves on the board of directors of Phoenix Tissue Repair.

Taylor C. Harris brings more than 20 years of finance and life science industry experience to MyoKardia where he leads the finance, accounting, information technology, facilities, corporate communications and investor relations functions.
Previously, Mr. Harris most served as Senior Vice President and Chief Financial Officer of Zeltiq Aesthetics, Inc., until that company’s acquisition by Allergan plc.  During that time, he was responsible for global finance, accounting, tax, treasury, investor relations, and information technology functions, as well as the company’s commercial operations, including customer service, product support, and inside sales.  Prior to Zeltiq, Mr. Harris served as Vice President and Chief Financial Officer at Thoratec Corporation (acquired by St. Jude Medical, Inc.).  Prior to joining Thoratec, Mr. Harris worked at JPMorgan Chase & Co. for over a decade in several capacities, including as a Vice President in the firm's Healthcare Investment Banking and Equity Research departments.  
Mr. Harris holds a Bachelor of Arts in Physics and Economics from the University of North Carolina at Chapel Hill, where he studied as a Morehead-Cain Scholar.

Ms. Ladd joins MyoKardia having most recently served as senior vice president and general counsel for CytomX Therapeutics, Inc.  Before joining CytomX in 2015, she was an independent consultant to biotechnology companies (including CytomX), supporting corporate growth by advising on corporate strategy, negotiations around collaborations, and clinical and regulatory issues, as well as acting as general counsel. Prior to her consultancy, she was president and chief executive officer of AGY Therapeutics, leading the company through a successful venture round and its transition to a clinical organization. Ms. Ladd also served as senior vice president and general counsel at Pharmacyclics, where she led various operating groups, including regulatory affairs, advised on corporate governance and compliance, structured negotiations for business development activities and led all the legal activities, including those related to the company’s intellectual property portfolio.  Earlier in her career, Ms. Ladd held a number of positions at Genentech, including vice president of corporate law and chief corporate counsel. 
Ms. Ladd began her career as an associate with Wilson, Sonsini, Goodrich & Rosati and Ware & Freidenrich (now DLA Piper).  She received her law degree from Stanford Law School, a master’s degree in animal nutrition and biochemistry from Cornell University and a bachelor’s degree in animal science from Pennsylvania State University.

Ingrid Boyes has more than 20 years of human resources and senior leadership experience across the insurance, banking and biotech industries. Prior to MyoKardia, Ms. Boyes was vice president and head of human resources for global product development at Roche. In this role, she was responsible for leading the human resources strategy globally for that function. Previously, she was at Genentech, where she held positions of increasing responsibility, including director of corporate staffing and diversity. She was also senior director of human resources for technical operations and prior to that, held a similar role leading human resources for North America commercial operations. 
Ms. Boyes holds a B.S. from the University of San Francisco and an MBA from Notre Dame de Namur University.

Marc Semigran, M.D., joined MyoKardia in December, 2016. Previously, he led the Massachusetts General Hospital Heart Failure and Cardiac Transplant Program as section head and medical director, from 2004 to 2016. In addition, he was principal investigator of the Harvard Regional Clinical Center of the National Heart, Lung, and Blood Institute Heart Failure Network. Dr. Semigran was a member of the internal medicine and cardiology staff of Massachusetts General for more than 25 years and is an associate professor at Harvard Medical School. He has published more than 140 peer-reviewed papers in cardiomyopathy, heart failure and cardiac transplantation, and served as editor for a leading textbook on heart failure. Dr. Semigran is a recipient of numerous National Institutes of Health and industry research awards, and has served as principal or co-investigator in several major clinical trials across various therapeutic areas. In addition, he has served in scientific and medical advisory capacities to such companies as GSK, Medtronic plc and Bayer.
Dr. Semigran earned A.B., A.M. and M.D. degrees from Harvard University. He completed his internal medicine residency and cardiology fellowship training at Massachusetts General.

Dr. Edelberg is a clinical cardiologist and vascular biologist, having served in leadership roles for two decades in both academic medicine and the biopharmaceutical industry. Most recently, Dr. Edelberg led cardiovascular drug development at Sanofi, where he spearheaded the development of Praluent® and oversaw the clinical development and global project teams involved in the MyoKardia partnership. Previously, Dr. Edelberg directed cardiovascular biomarker research at Bristol-Myers Squibb, where he served as the U.S. medical lead for Eliquis® and at Glaxo SmithKline.
From 1999 to 2006, Dr. Edelberg served as an attending coronary care unit (CCU) cardiologist and directed the Cardiac Vascular Biology Research Laboratory at Weill-Cornell Medical Center, with a specific research focus on cardiac stems cells and biomarkers of cardiac aging. Dr. Edelberg trained at the Massachusetts General Hospital (Internal Medicine), the Beth Israel Deaconess Medical Center in Boston (Cardiovascular Medicine) and Massachusetts Institute of Technology (Biology). Dr. Edelberg is an M.D., Ph.D., graduate of Duke University in Durham, North Carolina. 

Joe Lambing, Ph.D., has more than 20 years of drug development experience in the areas of cardiovascular disease, inflammation and oncology. During his career, Dr. Lambing has contributed to numerous NDA and IND filings for more than a dozen new chemical entities, as well as numerous filings to support a variety of clinical trials in other countries. Prior to joining MyoKardia, he was senior vice president of development for Portola Pharmaceuticals, where he oversaw all preclinical and pharmaceutical development activities since the company’s founding in 2003. Prior to Portola, Dr. Lambing served as director of drug safety and disposition for Millennium Pharmaceuticals’ San Francisco site, and director of DMPK and toxicology at COR Therapeutics.
Dr. Lambing holds a B.S. in chemistry and a Ph.D. in biochemistry from the University of Missouri, and was a postdoctoral fellow at the University of California, San Diego.